Blepharoclonus as a Potential Novel Clinical Marker in Parkinson’s Disease (P3-11.009)

Nestor Beltre(Hinge Health), Jason Margolesky(University of Miami), Joanne Wuu(University of Miami), Michael Benatar(University of Miami), Danielle S. Shpiner(University of Miami), Henry Moore(University of Miami), Ihtsham Haq(University of Florida), Matthew Feldman(University of Miami), Carlos Singer(University of Miami Health System), Sarah Marmol(University of Miami), Corneliu Luca(University of Miami Health System)

Neurology

April 25, 2023

10.1212/wnl.0000000000204169

Cited by 1

Related Papers

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

|The Lancet Neurology|2017|820

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease

|JAMA|2016|397

Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder

|Sleep Medicine|2013|391

Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

|The Lancet Neurology|2023|255

Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group

|Sleep Medicine|2013|238